Results 201 to 210 of about 2,850,431 (286)

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes   +7 more
wiley   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys   +14 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann   +7 more
wiley   +1 more source

A Specific tRNA Half, 3'tiRNA‐GlyGCC, Regulates Hypoxic Pulmonary Artery Smooth Muscle Cell Proliferation via Myrf‐Mediated Endoplasmic Reticulum Stress

open access: yesCell Proliferation, EarlyView.
A schematic diagram illustrating how 3′tiRNA‐GlyGCC promotes the endoplasmic reticulum stress (ERS) and proliferation in hypoxic pulmonary artery smooth muscle cells (PASMCs) by inhibiting the expression of myelin regulatory factor (Myrf), ultimately leading to pulmonary hypertension (PH).
Lixin Zhang   +11 more
wiley   +1 more source

DiaActive protocol: A randomized controlled trial of cognitive‐motor multicomponent exercise to reduce fall rate in older adults with diabetes

open access: yesDiabetic Medicine, EarlyView.
Abstract Introduction Older adults with diabetes have an increased risk of falls due to neuropathy, impaired bone health and cardiovascular disease, resulting in significant morbidity and mortality. Conventional fall‐prevention programmes primarily target strength and balance, while cognitive‐motor integration, essential for safe mobility in complex ...
Aksayan Arunanthy Mahalingasivam   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy